Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy

Abstract Three recent approvals and over 100 ongoing clinical trials make adeno‐associated virus (AAV)‐based vectors the leading gene delivery vehicles in gene therapy. Pharmaceutical companies are investing in this small and nonpathogenic gene shuttle to increase the therapeutic portfolios within t...

Full description

Bibliographic Details
Main Authors: Hanna J. Wagner, Wilfried Weber, Martin Fussenegger
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202004018
id doaj-3e9715ac034b476fb1e20d318f83b8c4
record_format Article
spelling doaj-3e9715ac034b476fb1e20d318f83b8c42021-05-05T07:56:41ZengWileyAdvanced Science2198-38442021-05-0189n/an/a10.1002/advs.202004018Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene TherapyHanna J. Wagner0Wilfried Weber1Martin Fussenegger2Department of Biosystems Science and Engineering ETH Zurich Mattenstrasse 26 Basel 4058 SwitzerlandFaculty of Biology University of Freiburg Schänzlestraße 1 Freiburg 79104 GermanyDepartment of Biosystems Science and Engineering ETH Zurich Mattenstrasse 26 Basel 4058 SwitzerlandAbstract Three recent approvals and over 100 ongoing clinical trials make adeno‐associated virus (AAV)‐based vectors the leading gene delivery vehicles in gene therapy. Pharmaceutical companies are investing in this small and nonpathogenic gene shuttle to increase the therapeutic portfolios within the coming years. This prospect of marking a new era in gene therapy has fostered both investigations of the fundamental AAV biology as well as engineering studies to enhance delivery vehicles. Driven by the high clinical potential, a new generation of synthetic‐biologically engineered AAV vectors is on the rise. Concepts from synthetic biology enable the control and fine‐tuning of vector function at different stages of cellular transduction and gene expression. It is anticipated that the emerging field of synthetic‐biologically engineered AAV vectors can shape future gene therapeutic approaches and thus the design of tomorrow's gene delivery vectors. This review describes and discusses the recent trends in capsid and vector genome engineering, with particular emphasis on synthetic‐biological approaches.https://doi.org/10.1002/advs.202004018AAV; adeno‐associated viruscapsid modificationsengineeringgene deliverymolecular switchesvector design
collection DOAJ
language English
format Article
sources DOAJ
author Hanna J. Wagner
Wilfried Weber
Martin Fussenegger
spellingShingle Hanna J. Wagner
Wilfried Weber
Martin Fussenegger
Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
Advanced Science
AAV; adeno‐associated virus
capsid modifications
engineering
gene delivery
molecular switches
vector design
author_facet Hanna J. Wagner
Wilfried Weber
Martin Fussenegger
author_sort Hanna J. Wagner
title Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
title_short Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
title_full Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
title_fullStr Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
title_full_unstemmed Synthetic Biology: Emerging Concepts to Design and Advance Adeno‐Associated Viral Vectors for Gene Therapy
title_sort synthetic biology: emerging concepts to design and advance adeno‐associated viral vectors for gene therapy
publisher Wiley
series Advanced Science
issn 2198-3844
publishDate 2021-05-01
description Abstract Three recent approvals and over 100 ongoing clinical trials make adeno‐associated virus (AAV)‐based vectors the leading gene delivery vehicles in gene therapy. Pharmaceutical companies are investing in this small and nonpathogenic gene shuttle to increase the therapeutic portfolios within the coming years. This prospect of marking a new era in gene therapy has fostered both investigations of the fundamental AAV biology as well as engineering studies to enhance delivery vehicles. Driven by the high clinical potential, a new generation of synthetic‐biologically engineered AAV vectors is on the rise. Concepts from synthetic biology enable the control and fine‐tuning of vector function at different stages of cellular transduction and gene expression. It is anticipated that the emerging field of synthetic‐biologically engineered AAV vectors can shape future gene therapeutic approaches and thus the design of tomorrow's gene delivery vectors. This review describes and discusses the recent trends in capsid and vector genome engineering, with particular emphasis on synthetic‐biological approaches.
topic AAV; adeno‐associated virus
capsid modifications
engineering
gene delivery
molecular switches
vector design
url https://doi.org/10.1002/advs.202004018
work_keys_str_mv AT hannajwagner syntheticbiologyemergingconceptstodesignandadvanceadenoassociatedviralvectorsforgenetherapy
AT wilfriedweber syntheticbiologyemergingconceptstodesignandadvanceadenoassociatedviralvectorsforgenetherapy
AT martinfussenegger syntheticbiologyemergingconceptstodesignandadvanceadenoassociatedviralvectorsforgenetherapy
_version_ 1721467742429642752